• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

    348.06 +6.40 (+1.87%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 811,433
    Open 350.00
    Bid (Size) 347.55 (40)
    Ask (Size) 347.57 (40)
    Prev. Close 341.66
    Today's Range 343.48 - 356.50
    52wk Range 127.99 - 356.50
    Shares Outstanding 22,205,642
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead ↗
    They haven't peaked yet. 
    Via The Motley Fool
    News headline image
    Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
    Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +41.0%
    +41.0%
    1 Month
    +18.7%
    +18.7%
    3 Month
    +34.9%
    +34.9%
    6 Month
    +49.1%
    +49.1%
    1 Year
    +163.5%
    +163.5%

    More News

    Read More
    News headline image
    Why This Tech Fund Made a $5.8 Million Bet on an AI Chip Stock Up Nearly 200% Post-IPO ↗
    Via The Motley Fool
    Topics Artificial Intelligence Initial Public Offering Regulatory Compliance
    Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum ↗
    Via Chartmill
    Krystal Biotech (NASDAQ:KRYS) Surges After Q1 Beat as VYJUVEK Revenue Hits $116.4M ↗
    Via Chartmill
    News headline image
    This AI Semiconductor Stock Beat the S&P 500 by 9 Points. A Fund Just Exited Completely ↗
    Via The Motley Fool
    Topics Artificial Intelligence Regulatory Compliance Stocks
    News headline image
    Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
    Via The Motley Fool
    News headline image
    Krystal (KRYS) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Krystal (KRYS) Q1 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Is Paymentus Stock a Buy After Palisades Investment Partners Increased Its Stake By $6 Million? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Is Amprius Technologies Stock a Buy After Palisades Investment Partners Initiated a Position Worth $4.8 Million? ↗
    Via The Motley Fool
    Topics Electric Vehicles Regulatory Compliance
    News headline image
    Palisades Investment Partners Initiated a Position in SkyWater Technology Stock. What Does This Mean for Investors? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
    Via The Motley Fool
    News headline image
    Is Vertex Pharmaceuticals' Empire in Trouble? ↗
    Via The Motley Fool
    News headline image
    Could This Under-the-Radar Healthcare Stock Set You Up for Life? ↗
    Via The Motley Fool
    News headline image
    Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗
    Via The Motley Fool
    News headline image
    Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
    Via The Motley Fool
    News headline image
    Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism ↗
    Via Stocktwits
    Topics Artificial Intelligence

    Frequently Asked Questions

    Is Krystal Biotech, Inc. - Common Stock publicly traded?
    Yes, Krystal Biotech, Inc. - Common Stock is publicly traded.
    What exchange does Krystal Biotech, Inc. - Common Stock trade on?
    Krystal Biotech, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Krystal Biotech, Inc. - Common Stock?
    The ticker symbol for Krystal Biotech, Inc. - Common Stock is KRYS on the Nasdaq Stock Market
    What is the current price of Krystal Biotech, Inc. - Common Stock?
    The current price of Krystal Biotech, Inc. - Common Stock is 348.06
    When was Krystal Biotech, Inc. - Common Stock last traded?
    The last trade of Krystal Biotech, Inc. - Common Stock was at 06/18/26 04:00 PM ET
    What is the market capitalization of Krystal Biotech, Inc. - Common Stock?
    The market capitalization of Krystal Biotech, Inc. - Common Stock is 7.73B
    How many shares of Krystal Biotech, Inc. - Common Stock are outstanding?
    Krystal Biotech, Inc. - Common Stock has 8B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.